Atezolizumab

FDA label information for this drug is available at DailyMed.

Use in Cancer

Atezolizumab is approved to treat:

• Breast cancer that is triple negative and has the PD-L1 protein. It is used with paclitaxel albumin-stabilized nanoparticle formulation in adults whose cancer is locally advanced, metastatic, or cannot be removed by surgery.¹
• Hepatocellular carcinoma (a type of liver cancer) that is metastatic or cannot be removed by surgery. It is used with bevacizumab in patients who have not received systemic therapy.
• Melanoma that has a certain mutation in the BRAF gene. It is used with cobimetinib fumarate and vemurafenib in adults whose cancer is metastatic or cannot be removed by surgery.
• Non-small cell lung cancer that has metastasized. It is used:
  • As first-line therapy in adults whose cancer has the PD-L1 protein and does not have a mutation in the EGFR gene or the ALK gene.
  • With bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as first-line therapy in adults with non-squamous cancer that does not have a mutation in the EGFR gene or ALK gene.
  • In adults whose cancer has gotten worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the EGFR gene or ALK gene, atezolizumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations.
• Small cell lung cancer. It is used with carboplatin and etoposide as first-line therapy in adults with extensive-stage cancer.
• Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in:
  • Adults whose cancer has the PD-L1 protein and cannot be treated with cisplatin.¹
  • Adults whose cancer cannot be treated with platinum chemotherapy or has gotten worse during or after treatment with platinum chemotherapy.¹

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that atezolizumab provides a clinical benefit in these patients.

Atezolizumab is also being studied in the treatment of other types of cancer.

More About Atezolizumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Atezolizumab - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Cancer Therapies

Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer

Immunotherapy Effective in Alveolar Soft Part Sarcoma

Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer

For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival

Clinical Trials Accepting Patients

Find Clinical Trials for Atezolizumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.